ViiV Healthcare Ltd., a joint venture of GlaxoSmithKline Plc and two other drugmakers, plans to license pediatric versions of its HIV drug abacavir to a patent-sharing body backed by the United Nations to improve children's access to treatment. ViiV will grant the voluntary license to the medicines patent pool for the drug in the 118 countries where 99 percent of children with HIV live, it said in a statement yesterday.